Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

Topic: Mylan

    Note: these results are not from the primary (high quality) database.

Ads by Google

In the News (Thu 24 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

Mylan Laboratories Comments on Icahn Letter Mylan, King and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of Mylan and King in favor of the acquisition. In addition, the documents filed with the SEC by Mylan may be obtained free of charge by directing such request to: Mylan Laboratories Inc., Attention: Investor Relations, 1500 Corporate Drive, Canonsburg, PA 15317, or from Mylan's website at http://www.mylan.com. Information about the executive officers and directors of Mylan and their ownership of Mylan common stock is set forth in the proxy statement for Mylan's 2004 Annual Meeting of Shareholders, which was filed with the SEC on June 28, 2004. www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-19-2004/0002467228&EDATE=

Mylan Laboratories Announces Preliminary First Quarter Dilut... - Jul. 11, 2005 Mylan, its executive officers and its directors may be deemed to be participants in Mylan's solicitation of proxies from shareholders in connection with the Annual Meeting scheduled to be held on October 28, 2005. Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products. Mylan's modified "Dutch Auction" self-tender, which was originally due to expire at 5:00 p.m., New York City time, on Friday, July 15, 2005, has been extended seven hours and will now expire at 12:00 midnight, New York City time, on Friday, July 15, 2005, unless Mylan further extends the self-tender. money.cnn.com /services/tickerheadlines/prn/200507110630PR_NEWS_USPR_____NYM094.htm

Mylan Laboratories Inc. News Information at Business.com Mylan Laboratories Inc., one of the country's largest makers of generic prescription drugs, said Tuesday that first-quarter profit declined 48 percent from last year, due to lower sales and increased research, restructuring and legal costs. Mylan Laboratories Inc. expects to buy nearly 51.3 million shares of its common stock, or about 19 percent of the shares outstanding, the generic drug maker said Sunday. Mylan Laboratories Inc. said Thursday that the Food and Drug Administration approved its generic version of Purinethol, a chemotherapy drug sold by Teva Pharmaceutical Industries. www.business.com /directory/pharmaceuticals_and_biotechnology/manufacturers/mylan_laboratories_inc/news

"company+drug+mylan": Digest Drug, Drug in Sport Mylan Laboratories Inc. and its subsidiaries are engaged in the development, licensing, manufacturing and marketing of generic and proprietary finished pharmaceutical and wound care products. Mylan Laboratories Inc. is a diversified pharmaceutical company with a core generic business; a growing branded presence and varied drug delivery capabilities. Mylan plans more drug price increases Thursday, January 28, 1999 By Teresa F. Lindeman, Post-Gazette Staff Writer Mylan Laboratories Inc. yesterday said it was sticking by its strategy of... www.pillfactor.com /drug-13/company-drug-mylan.html

MSN Money - MYL Key Developments: Investing Mylan Laboratories, Inc. announced that the U.S. District Court for the District of New Jersey issued an opinion, which concluded that the relevant patent may be properly construed to expressly claim topiramate. Mylan intends to use the proceeds from the issue to fund a portion of its purchase of up to 48.8 million shares of its common stock (up to $1 billion) pursuant to its previously announced modified Dutch auction self-tender offer which was commenced on June 16, 2005. Mylan Laboratories, Inc. announced that it expects second quarter earnings per diluted share to be $0.17 to $0.19, compared to $0.33 in the second quarter of fiscal 2004. news.moneycentral.msn.com /ticker/sigdev.asp?Symbol=MYL&PageNum=2

StockSelector.com News for MYL Mylan Laboratories Inc. ( MYL) today provided a preliminary range of first quarter fiscal 2006 adjusted diluted EPS of between $0.24 and $0.26 and GAAP diluted EPS of between $0.14 and $0.16, which includes $0.03 for a contingent liability with respect to previously-disclosed lorazepam and clorazepate product litigation. Mylan Laboratories Inc. ( MYL) announced today that it will host a conference call and live webcast in conjunction with the release of its first quarter fiscal 2006 financial results on Tuesday, July 19, 2005 at 8:30 AM EDT. Mylan Laboratories Inc. (  ) will host a conference call and live webcast in conjunction with the release of its first quarter fiscal 2006 financial results on Tuesday, July 19, 2005 at 8:30 AM EDT. www.stockselector.com /news.asp?symbol=MYL

Federal Trade Commission v. Mylan Laboratories, Inc. Defendants are Mylan Laboratories, Inc., Cambrex Corporation, Profarmaco S.R.L. and Gyma Laboratories of America, Inc. The FTC alleges that the defendants engaged and are engaging in unfair methods of competition in or affecting commerce in violation of § 5(a) of the FTC Act, 15 U.S.C. § 45(a). The premise of the States’ request is that Mylan’s competitors in the generic drug industry, though not parties to the exclusive licenses nor members of the alleged conspiracy, raised their prices as a consequence of Mylan’s actions. Mylan Labs, is an action brought by thirty-two states against defendants for violations of §§ 1 and 2 of the Sherman Act, 15 U.S.C. §§ 1 and 2, as well as various state antitrust laws. lw.bna.com /lw/19990720/983114.htm

Mylan Laboratories Inc. - Investor FAQ Mylan was founded in 1961 and went public in February, 1973. Mylan currently pays a quarterly dividend of $.03 per share, all such dividends being subject to Board approval. Mylan trades under the stock symbol MYL on the NYSE. investor.mylan.com /phoenix.zhtml?c=66563&p=irol-faq

Office of the Attorney General: Mylan Laboratories Settlement Mylan was accused of orchestrating an illegal price increase of more than 2000 percent for two generic drugs, lorazepam and clorazepate, which are used to treat Alzheimer's disease and other afflictions. In addition, Mylan has agreed to the inclusion of certain restrictions in its supplier agreements in order to restore competitive balance to the pharmaceutical market, and to reimburse the states for up to $8 million in legal and investigative costs. In 1998, 32 state attorneys general and the DC Corporation Counsel sued Pittsburgh-based Mylan, New Jersey-based Cambrex Corporation and SST Corporation, Italian pharmaceutical ingredient manufacturer Profarmaco S.r.l., and New York-based drug distributor Gyma, alleging that the companies had participated in a price-fixing and monopolization scheme led by Mylan. occ.dc.gov /occ/cwp/view,a,1223,q,531408.asp

Drug Store News: Mylan Laboratories Mylan believes it is the first to file ANDAs with the FDA for 5 mg and 10 mg Ditropan XL and may be eligible for 180 days of market exclusivity. Mylan Laboratories has received tentative approval from the FDA for its ANDAs for oxybutynin chloride extended-release tablets in 5 mg and 10 mg dosage strengths. Mylan Chief Executive Officer Robert Coury said that because of accounting issues, "it is highly unlikely" the parties would consummate the merger by Feb. 28, after which either party may terminate the merger agreement. www.findarticles.com /p/articles/mi_m3374/is_2_27/ai_n10018282

Mylan Laboratories Inc. - E-Commerce Mylan is committed to promoting electronic commerce within our company and in the pharmaceutical industry. At Mylan, we focus our efforts on "value-added" e-commerce solutions that make it easier for customers to do business with us. We believe that utilizing technology to improve the way we communicate and interact with our customers, shareholders, and the public is a vital and necessary strategy. ec.mylan.com

Drug Store News: Mylan Laboratories Mylan Laboratories stated it would not be put off by its largest shareholder, Carl Icahn, who filed a letter with the Securities and Exchange Commission on Nov. 1, denouncing Mylan's effort to acquire King Pharmaceuticals. In a statement issued by Mylan, Chief Executive Officer Robert Coury noted, "Mylan's board of directors and management will continue to be thorough in their analysis of King and its recent disclosures and will neither be distracted nor deterred by Mr. In other news, Mylan was granted tentative approval for its ANDA for pioglitazone HC1 tablets in 15 mg, 30mg and 45 mg dosages. www.findarticles.com /p/articles/mi_m3374/is_16_26/ai_n7587005

Mylan Laboratories, Inc. - 11/29/00 The complaint alleged that Mylan, Cambrex Corporation, Profarmaco, and Gyma violated the Federal Trade Commission Act by agreeing to restrain trade and conspiring to monopolize the generic lorazepam market and the generic clorazepate market. Defendant Profarmaco, an API manufacturer, supplied Mylan and most of its competitors with lorazepam API and clorazepate API; Cambrex is the parent company of Profarmaco. Mylan will pay $100 million in disgorged profits into a fund to compensate injured consumers and state agencies. www.ftc.gov /opa/2000/11/mylanfin.htm

Mylan Laboratories Mylan Laboratories Inc. and its subsidiaries are engaged in the development, licensing, manufacturing, and marketing of numerous generic and proprietary finished pharmaceutical and wound care products. Since July 1, 1996 to the present Mylan has received 19 ANDA approvals, the highest amount of approvals in the generic industry, and more than twice the amount of the second ranked company. Although generic pharmaceuticals remain a core focus for the company, Mylan's diversified approach to the pharmaceutical market is the catalyst for future long-term growth. www.advisorinsight.com /pub/indexes/400_mi/MYL_mi.htm

CARISOPRODOL - Mylan Mylan Laboratories Inc - Company profile and brandsMylan Laboratories Inc is one of the 11000 corporations and 25000 brands for which Transnationale and Co. provides social, financial and environmental... Mylan Pharmaceuticals, the Morgantown-based division of Mylan Laboratories of Canonsburg, Pa... Mylan Labs Chief Defends His DoctrineThe strategy to acquire King Pharma was a correct one, says CEO Robert Coury. bestdeal.home.pl /carisoprodol/mylan.html

Mylan Laboratories to buy King Pharmaceuticals for about $4 billion in stock Mylan and other generic companies are trying to smooth out that boom-bust cycle by filling their portfolios with branded drugs. Mylan did an extensive review of King and the SEC investigation and was "comfortable in all areas," Coury said. Mylan on Monday also reported first-quarter results, earning profits of $82 million, or 30 cents per share, compared with $83.8 million, or 30 cents per share, during the same period last year. www.sfgate.com /cgi-bin/article.cgi?file=/news/archive/2004/07/26/financial0752EDT0008.DTL&type=printable

Mylan Laboratories "under perform" newratings.com CE Unterberg Towbin expresses its concern regarding the limited visibility into Mylan Laboratories' generic drug portfolio and the growth catalysts for the overall generic drug industry in the near term. The FDA had decided to withdraw its final marketing approval for Mylan Laboratories' generic drug in July this year, CE Unterberg Towbin says. Shares of Mylan Laboratories, a US-based pharmaceutical company, are currently trading at $15.36. www.newratings.com /analyst_news/article_458118.html

Mylan Laboratories Inc. - Company Profile - Pharmaceutical Business Review Mylan Laboratories is a pharmaceutical company specializing in the development, manufacture and marketing of generic and branded pharmaceutical products. Mylan's generic product portfolio covers a variety of dosage forms including immediate and extended-release oral tablets and capsules and transdermal patches, as well as repackaging and marketing multi-source and single-source products in unit dose form for the institutional marketplace. Mylan was instrumental in creating the generic drug industry and time and again has introduced innovations in products and business strategies. www.pharmaceutical-business-review.com /companyprofile.asp?guid=2C9A57D1-DA29-4CD5-A31A-E6FEFFE838C2

Espicom - Mylan Laboratories Generics Company Report Mylan was also one of the first companies to bring a generic version of omeprazole to the US market. Mylan attributes this fall in revenues to a drop off in omeprazole revenues and a lack of major new product launches for much of fiscal 2005. Founded in 1961, Mylan Laboratories is one of the largest US generic drug manufacturers. www.espicom.com /web.nsf/structure/ph_bkscmylan?OpenDocument

07/13/2000: Cornyn Announces Settlement with Mylan Laboratories Mylan's board of directors has already approved the terms of the settlement in principle. Mylan will also reimburse the states up to $8 million for legal and investigative costs. In addition to the amount of the restitution and damages of the settlement in principle, Mylan has agreed to certain restrictions in its supplier agreements in order to restore competitive balance to the pharmaceutical market. www.oag.state.tx.us /newspubs/newsarchive/2000/20000713mylansettle.htm

Mylan Laboratories win generic OKs - billingsgazette.com First, Mylan announced on July 26 that it would acquire Tennessee-based drug maker and distributor King Pharmaceuticals in a deal that many analysts labeled as too expensive, causing its stock prices to dip from $16.55 to $14.76 over the course of two days. Mylan will probably be competing against other generic companies to market these drugs. PITTSBURGH, P.A. - Mylan Laboratories shook off a shaky two weeks Tuesday with some good news - the Food and Drug Administration granted final approval for a generic version of the hypertension drug Lopressor and tentative approval of Pfizer's popular allergy and depression medications Zyrtec and Zoloft. www.billingsgazette.com /index.php?id=1&display=rednews/2004/08/25/build/business/63-mylan-labs-generic.inc

Mylan Laboratories Inc. - Fact Sheet - Hoover's Mylan Laboratories knows you may not recognize the names of its drugs, but it hopes you'll appreciate their prices. Mylan is one of the largest manufacturers of prescription generic drugs in the US. Mylan has shut down its branded drugs division, which focused on cardiology, dermatology, and neurology. www.hoovers.com /mylan-labs/--ID__11030--/free-co-factsheet.xhtml

MYLAN LABORATORIES SETTLEMENT: Refund checks sent to Michiganders Between 1998 and 1999, Mylan raised the wholesale cost of a 500-pill bottle of the lorazepam, a drug that treats conditions like hypertension and chemotherapy-induced nausea, from $7.30 to $190.50, said Genna Beaudoin Gent, a spokeswoman for the Michigan Attorney General's office. After the settlement with Mylan, each state worked with pharmacists to establish lists of those who had prescriptions filled with the two drugs. More than 4,600 Michigan residents will begin receiving checks averaging $170 each this week as a result of a multimillion-dollar settlement between 31 states and Mylan Laboratories,which sold prescription drugs at inflated prices in 1998 and 1999. www.freep.com /money/business/pills20_20020620.htm

Mylan Laboratories Inc. - Careers Mylan is an Equal Opportunity/Affirmative Action Employer EEO/AA/M-F-V-D. © Copyright 2002 Mylan Laboratories Inc. Thank you for your interest in Mylan Laboratories Inc. This site will provide you with a current listing of career opportunities within the Mylan organization. We understand that the continued success of our company depends upon the importance of our employees in our future and we will support and encourage them to reach their full potential. www.mylan.com /careers

NYSE, New York Stock Exchange > About the NYSE > Listed Companies > Listed Company Directory Mylan Laboratories Inc. Mylan Laboratories Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The Generic Segment consists of two business units, Mylan Pharmaceuticals Inc. (MPI) and UDL Laboratories, Inc. (UDL), both of which are wholly owned subsidiaries of Mylan. The Brand Segment consists of two business units, Mylan Bertek Pharmaceuticals Inc. (Mylan Bertek) and Mylan Technologies, Inc. (Mylan Tech), both of which are wholly owned subsidiaries of Mylan. www.nyse.com /listed/myl.html

THE INVISIBLE HAND AT WORK WITH MYLAN LABORATORIES Mylan Labs also keeps the prices down of the name brand pharmaceuticals by heavy competition, which is the key to affordable health care in the future. One such case is Mylan Laboratories, a pharmaceutical company which manufactures generic drugs. Many people who do not have medical insurance are happy that there are companies like Mylan seeking their own personal gain, by which they can attain drugs without a huge financial burden. members.aol.com /geo13/labs.htm

Online media mentions for Mylan Laboratories One exception there is Mylan Laboratories, which in July agreed to buy King Pharmaceuticals for $4.1bn in stock. [excerpt] Mylan Laboratories (nyse: MYL - news - people), seeking to acquire King for $4 billion, may not be happy with the restatement news, but for one Mylan investor... Mylan Laboratories Inc. lost a court bid to begin selling a generic... www.cancer-help.org /corp/Mylan_Laboratories.html

Mylan Laboratories News Mylan Laboratories Inc. said Tuesday that profits fell 48 percent from last year, as it downplayed concerns that its top-selling generic medication is under increased government scrutiny after being linked to... Mylan Pharmaceuticals, the Morgantown-based division of Mylan Laboratories of Canonsburg, Pa., has donated a Scanning Electron Microscope to the Department of Biology in the Eberly College of Arts and Sciences... Mylan Laboratories Inc. on Tuesday said it will buy back up to $1.25 billion worth of its shares, or 25 percent of the company's outstanding stock, as the drug maker tries to prop up its stock price after a... www.topix.net /com/myl

Mylan Laboratories Generics Company Intelligence Report Mylan Laboratories was incorporated in Pennsylvania in August 1970. Mylan employs around 2,500 people across its units. Laboratories, and branded products through its Bertek Pharmaceuticals unit. www.biz-lib.com /ZEB67403.html

Mylan Laboratories (MYL) Stock Research - Stock Quotes, Charts, News and Analysis Mylan Laboratories Inc. and its subsidiaries are engaged in developing, licensing, manufacturing, marketing and distributing generic and branded pharmaceutical products. Mylan Laboratories data - This stock research material comes from the finest financial sites on the web. Bristol Myers Squibb • Barr Laboratories • Pharmaceutical Resources • Impax Laboratories • Genta • Penwest Pharmaceuticals Co. www.investorguide.com /cgi-bin/research.cgi?name=MYL

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.